KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL

Abstract

We analyzed the influence of donor killer-cell immunoglobulin-like receptor (KIR) gene haplotypes on the risk for relapse and the probability of event-free survival (EFS) in children with acute lymphoblastic leukemia who received human leukocyte antigen-haploidentical transplantation of ex vivo T-cell-depleted peripheral blood stem cells. The KIR gene haplotype was evaluated in 85 donors, and the KIR B content score was determined in the 63 KIR haplotype B donors. Patients transplanted from a KIR haplotype B donor had a significantly better EFS than those transplanted from a KIR haplotype A donor (50.6% vs 29.5%, respectively; P = .033). Moreover, a high donor KIR B-content score was associated with a significantly reduced risk for relapse (Log-rank test for trend, P = .026). These data indicate that KIR genotyping should be included in the donor selection algorithm for haploidentical transplantation in children with acute lymphoblastic leukemia with the aim of choosing, whenever possible, a KIR haplotype B donor with a high KIR B-content score.

Figure 1

Cumulative incidence of relapse (A) and Kaplan-Meier estimate of event-free survival (B) according to the KIR haplotype of the donor for the whole population of patients. Cumulative incidence of relapse (C) and Kaplan-Meier estimate of event-free survival (D) according to the KIR B-content score of the donor for all patients.